8-K: uniQure Announces 2024 Financial Results and Highlights Clinical Progress, Expects Cash to Fund Operations into Second Half of 2027

uniQure reports 2024 financial results, highlights progress in Huntington's disease and other gene therapy programs, and anticipates funding operations into the second half of 2027.

Summary

• uniQure announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company highlighted progress across its business, including alignment with the FDA on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease.
• Patient enrollment is complete in the third cohort of the Phase I/II study of AMT-130.
• Dosing has begun in the Phase I/II study of AMT-260 in mesial temporal lobe epilepsy (mTLE), with protocol changes implemented to expand study inclusion criteria.
• Enrollment is complete for the first cohorts in the Phase I/II studies of AMT-191 in Fabry disease and AMT-162 in SOD1-ALS, with favorable recommendations from the Independent Data Monitoring Committees (IDMC).
• As of December 31, 2024, uniQure had approximately $367.5 million in cash and cash equivalents.
• Combined with $80.7 million in net proceeds from a recent financing, the company expects to fund operations into the second half of 2027.
• Revenue for the year ended December 31, 2024, was $27.1 million, compared to $15.8 million in 2023.
• Research and development expenses were $143.8 million for the year ended December 31, 2024, compared to $214.9 million in 2023.
• The net loss for the year ended December 31, 2024, was $239.6 million, or $4.92 basic and diluted loss per ordinary share, compared to $308.5 million net loss for the same period in 2023, or $6.47 basic and diluted loss per ordinary share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant clinical progress, FDA alignment, and a strong financial position. The company's strategic actions to reduce cash burn and extend its cash runway are also viewed favorably.

Positives

• FDA alignment on Accelerated Approval pathway for AMT-130 is a major milestone.
• RMAT designation has enabled productive dialogue with the FDA.
• Patient enrollment is progressing in multiple clinical programs.
• Strategic actions, including the sale of the Lexington manufacturing facility and company-wide restructuring, have reduced cash burn and strengthened the financial position.
• The company has a strong cash position expected to fund operations into the second half of 2027.
• Revenue increased year-over-year due to higher license and collaboration revenue.
• R&D expenses decreased, contributing to a lower net loss.

Negatives

• The company reported a net loss of $239.6 million for the year ended December 31, 2024.
• Cash and cash equivalents decreased from $617.9 million as of December 31, 2023, to $367.5 million as of December 31, 2024, although this was partially offset by a recent financing.
• Contract manufacturing revenue decreased by $4.7 million due to the divestment of the Lexington facility.

Risks

• Clinical trial results may not be favorable.
• Interactions with regulatory authorities may affect the timing and progress of clinical trials and regulatory approvals.
• The company may face challenges in building and maintaining the infrastructure and personnel needed to achieve its goals.
• The company's effectiveness in managing clinical trials and regulatory processes is uncertain.
• Gene therapies may not continue to be developed and accepted.
• The company may not be able to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials.
• The company may face challenges in obtaining, maintaining, and protecting intellectual property.
• The company may need to raise additional capital in the future.

Future Outlook

uniQure expects its cash, cash equivalents, and investment securities to be sufficient to fund operations through the second half of 2027, including the potential BLA submission and U.S. commercial launch of AMT-130. The company plans to continue advancing its pipeline of gene therapies and providing updates on its clinical programs.

Management Comments

• Matt Kapusta, chief executive officer of uniQure, stated that 2024 was transformative for uniQure, marked by significant clinical and operational progress.
• Mr. Kapusta highlighted the alignment with the FDA on key elements of the Accelerated Approval pathway for AMT-130, bringing the company closer to delivering the first potentially disease-modifying treatment for Huntington's disease.
• Mr. Kapusta noted that the company took decisive steps in 2024 to streamline its organization, including the sale of its Lexington manufacturing facility and a company-wide restructuring that significantly reduced its cash burn and strengthened its financial position.

Industry Context

uniQure is a leading gene therapy company focused on developing transformative therapies for severe medical needs. The company's progress in Huntington's disease and other gene therapy programs positions it as a key player in the rapidly evolving field of genomic medicine. The alignment with the FDA on the Accelerated Approval pathway for AMT-130 could set a precedent for other gene therapy companies seeking to develop treatments for rare and debilitating diseases.

Comparison to Industry Standards

• uniQure's cash runway extending into the second half of 2027 is relatively strong compared to other gene therapy companies of similar size, such as Sangamo Therapeutics and Voyager Therapeutics, which often require more frequent capital raises.
• The reduction in cash burn by approximately $70 million per year through restructuring and facility sale is a significant improvement, placing uniQure in a more sustainable financial position compared to peers that are still heavily investing in manufacturing infrastructure.
• The agreement with the FDA on the use of cUHDRS as an intermediate clinical endpoint for AMT-130 is a positive development, as regulatory pathways for gene therapies in neurological disorders are often challenging and require innovative approaches.

Stakeholder Impact

• Shareholders: The company's progress and financial stability are positive for shareholders.
• Employees: The company's restructuring has impacted employees, but the remaining workforce is focused on key programs.
• Patients: The company's progress in developing gene therapies offers hope for patients with severe medical needs.
• Suppliers: The company's financial stability ensures continued partnerships with suppliers.
• Creditors: The company's strong cash position reduces credit risk for creditors.

Next Steps

• The Company has scheduled a Type B meeting with the FDA in the first quarter of 2025 to discuss chemistry, manufacturing and control (CMC) requirements to support its planned BLA submission.
• A separate Type B meeting to discuss the pivotal statistical analysis plan for the BLA is anticipated to take place in the second quarter of 2025.
• The Company expects to provide a regulatory update in the second quarter of 2025, including the expected timing of a potential BLA submission.
• The Company expects to provide an initial safety update on the third cohort of AMT-130 in the second quarter of 2025.
• The Company expects to present data from its ongoing Phase I/II studies of AMT-130 in the third quarter of 2025.
• The Company expects to initiate enrollment in the second dose cohort in the AMT-191 study in the second quarter of 2025.
• The Company expects to present initial data from the AMT-191 study in the second half of 2025.
• The Company expects to present initial data from the AMT-260 study in the first half of 2026.
• The Company expects to present initial data from the AMT-162 study in the first half of 2026.

Key Dates